ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1449 • ACR Convergence 2022

    Incidence and Risk Factors for Active Tuberculosis in Patients with Systemic Lupus Erythematosus: A Multicenter Prospective Cohort Study

    Lifan Zhang1, xiaoqing zou2, Lantian Xie3, Jianghao Liu3, zhengrong yang4, qifei cao4, Chunlei Li5, Xiaochuan Sun5, Fengchun ZHANG6, Yan Zhao7, Xiaofeng Zeng8 and Xiaoqing Liu1, 1Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Clinical Epidemiology Unit, Peking Union Medical College, International Clinical Epidemiology Network; Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 2Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 3Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China, 4Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 5Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, 6Peking Union Medical College Hospital, Beijing, China, 7Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, 8Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China

    Background/Purpose: The burden of tuberculosis (TB) and systemic lupus erythematosus (SLE) in China are both the second largest in the world. Patients with SLE are…
  • Abstract Number: 1433 • ACR Convergence 2022

    A 48-week Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis

    Ulf Müller-Ladner1, Karl Gaffney2, Deepak Jadon3, Marco Matucci-Cerinic4, Eugenio Chamizo Carmona5 and Janet Addison6, 1JLU Campus KK, Bad Nauheim, Germany, 2Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, 3Cambridge University, Cambridge, United Kingdom, 4University of Florence, Florence, Italy, 5Hospital de Mérida, Mérida, Spain, 6Biogen Idec Ltd, Maidenhead, United Kingdom

    Background/Purpose: SB5, a biosimilar to reference adalimumab (ADL), received marketing authorisation in 2017 (EU) and 2019 (US) based on pre-clinical and clinical phase I and…
  • Abstract Number: 1448 • ACR Convergence 2022

    Utility of Digital Signals and Patient Reported Data Gathered in a Decentralized Study to Predict SLE Patient-Reported Flares

    Eldon Jupe1, Gerald Lushington2, Mohan Purushothaman1, Fabricio Pautasso1, Georg Armstrong1, Arif Sorathia1, Jessica Crawley1, Vijay Nadipelli3, Bernie Rubin4, Ryan Newhardt1, Melissa Munroe1 and Brett Adelman1, 1Progentec Diagnostics, Inc., Oklahoma City, OK, 2Progentec Diagnostics, Inc., Oklahoma City, OR, 3GlaxoSmithKline, Philadelphia, PA, 4GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by varied immune dysregulation. SLE patients often experience episodic flares, leading to organ damage…
  • Abstract Number: 1447 • ACR Convergence 2022

    Serum Cytokine Profiling Reveals Elevated Levels of S100A8/A9 and MMP-9 in Systemic Lupus Erythematosus Patients with Cognitive Impairment Independently of Disease Activity and Inflammatory Markers

    Carolina Munoz1, Michelle Barraclough2, Juan Pablo Diaz-Martinez1, Jiandong Su1, Kathleen Bingham3, Mahta Kakvan1, Maria Carmela Tartaglia4, Leslet Ruttan5, May Choi6, Dennisse Bonilla1, Simone Appenzeller7, Patricia Katz8, Dorcas Beaton9, Robin Green5, Joan Wither10 and Zahi Touma1, 1Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 2Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada, 3Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, 4University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, 5University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, 6Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, 7Unicamp, Campinas, São Paulo, Brazil, 8UCSF, San Rafael, CA, 9Institute for Work & Health, Toronto, ON, Canada, 10Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Cognitive impairment (CI) is one of the most common manifestations of neuropsychiatric lupus(NPSLE), which may occur in the absence of active Systemic Lupus Erythematosus…
  • Abstract Number: 1443 • ACR Convergence 2022

    Lymphadenopathy in Systemic Lupus Erythematosus: Clinical Characteristics and Prognostic Features

    Eleni Papachristodoulou, Daniel Magliulo and Vasileios Kyttaris, Beth Israel Deaconess Medical Center, Boston, MA

    Background/Purpose: Patients with SLE often develop lymphadenopathy (LAD), regarded as a relatively common manifestation of the disease. Its clinical significance has not yet been elucidated.…
  • Abstract Number: 1393 • ACR Convergence 2022

    Lung Involvement in Early Rheumatoid Arthritis, Interim Analysis of the FINDRA Prospective Study

    Marie Doyen1, Marie Perrot2, Benoit Ghaye3, Emilie Sapart1, Deniz Zan3, Aleksandra avramovska1, Tatiana Sokolova4, maria stoenoiu1, sandra koenig2, antoine froidure2 and Patrick Durez5, 1Rheumatology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 2Pulmonology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 3Radiology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 4Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium, 5Institute de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc - Université Catholique de Louvain (UCL), Brussels, Belgium

    Background/Purpose: The prevalence of lung involvement in rheumatoid arthritis (RA) remains elusive. We set up a prospective study to detect ILD, bronchiolitis and nodules in…
  • Abstract Number: 1425 • ACR Convergence 2022

    Treatment Persistence and Switching Patterns of ABP 501 (AMGEVITA®) in German Patients with Rheumatic Diseases

    Ran Jin1, Silvia Kruppert2, Florian Scholz2, Marc Hammer2, Greg Kricorian1, David Collier3 and Jonathan Kay4, 1Amgen, Inc., Thousand Oaks, CA, 2IQVIA, Frankfurt, Germany, 3Amgen Inc., Simi Valley, CA, 4Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA

    Background/Purpose: ABP 501 is the first adalimumab (ADA) biosimilar approved by the European Medical Association and the Food and Drug Administration for the treatment of…
  • Abstract Number: 1439 • ACR Convergence 2022

    Lymphatic Delivery of Etanercept Achieves Significant Improvements in Rheumatoid Arthritis Disease Measures at 50% of the Standard Dose for Patients with an Inadequate Response to Subcutaneous Injections

    Alan Smith1, Pei-Ling Roerig1, Jacob Cason2, David Fancis2, Brian Cooley2, Mike Royal3, Vibeke Strand4, John Goldman5, Roel Querubin6 and Russell Ross2, 14P Therapeutics, Peachtree Corners, GA, 2Sorrento Therapeutics, Atlanta, GA, 3Sorrento Therapeutics, San Diego, CA, 4Stanford University School of Medicine, Stanford, CA, 5Northside Hospital, Atlanta, GA, 6Atlanta Research Center for Rheumatology, Marietta, GA

    Background/Purpose: The lymphatic system plays an integral role in the pathology of rheumatoid arthritis (RA)1 and mediates local RA flares2, yet most biologic therapies are…
  • Abstract Number: 1341 • ACR Convergence 2022

    Clinical Outcomes of COVID-19 Vaccination and Booster in Patients with Autoimmune Inflammatory Rheumatic Diseases

    Silera Holguin Balbuena, Anna Radisic, Sarah Goodman, Shreya Gor, Beatrice Wood, Alexander Shahin, Kelara Samuel, Rahul Mhaskar and John Carter, University of South Florida, Tampa, FL

    Background/Purpose: The spread of COVID-19 began in December 2019 and quickly escalated into a global pandemic resulting in millions of deaths. Many factors are associated…
  • Abstract Number: 1402 • ACR Convergence 2022

    Late Onset Rheumatoid Arthritis Has a Similar Remission Rate as Younger Onset Rheumatoid Arthritis: Results from an Ontario Rheumatoid Arthritis Registry

    Xiuying Li1, Angela Cesta1, Mohammad Movahedi2 and Claire Bombardier3, 1University Health Network, Toronto, ON, Canada, 2Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada

    Background/Purpose: The prevalence of rheumatoid arthritis (RA) in persons 60 years or older is estimated to be 2%. Late onset rheumatoid arthritis (LORA) is a…
  • Abstract Number: 1450 • ACR Convergence 2022

    Impact of Time to Remission, Flares and Time on Immunosuppressives on the Estimated Glomerular Filtration Rate in Lupus Nephritis

    KONSTANTINOS TSELIOS1, Dafna Gladman2, Jiandong Su3 and Murray Urowitz4, 1McMaster University, Population Health Research Institute, Hamilton, ON, Canada, 2Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 3Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, 4University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada

    Background/Purpose: Time to complete remission, subsequent flares and time on immunosuppressives after complete remission are major determinants of the progression to advanced chronic kidney disease…
  • Abstract Number: 1434 • ACR Convergence 2022

    Retrospective Analysis of Tocilizumab-induced Neutropenia in Patients with Rheumatoid Arthritis

    YoungEun Kim1, Soo Min Ahn1, Ji Seon Oh2, Yong Gil Kim1, Chang Keun Lee1, Bin Yoo1 and Seokchan Hong1, 1Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, 2Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea

    Background/Purpose: Neutropenia has been reported as one of the most frequent adverse events of tocilizumab. We conducted a retrospective cohort study to determine the risks…
  • Abstract Number: 1330 • ACR Convergence 2022

    Impact of COVID-19 Severity on Physical Function, Mobility, Falls and Fractures Among Older Patients After Hospitalization: A Longitudinal Study

    Clara Wong1, Diego Cabrera2, Mary Geda3, Andrew Cohen3, Lauren Ferrante3, Alexandra Hajduk3 and Evelyn Hsieh2, 1Yale School of Public Health, New Haven, CT, 2Section of Rheumatology, Allergy and Immunology, Yale School of Medicine, New Haven, CT, 3Yale School of Medicine, New Haven, CT

    Background/Purpose: No longitudinal studies have examined the impact of COVID-19 or COVID-19 severity on physical function and disability outcomes among older adults. Multiple factors, including…
  • Abstract Number: 1446 • ACR Convergence 2022

    Contrast Enhaced Articular Magnetic Resonance Imaging (MRI) and Health Related Quality of Life in SLE Patients

    Tarek Carlos Salman-Monte1, Patricia Corzo2, Ivan Garcia-Duitama3, ANA Agustí Claramunt3, Irene Carrion Barbera4, Salvatore Marsico3 and Jordi Monfort5, 1Hospital del Mar/Parc de Salut Mar-IMIM/UEC-AIS, Barcelona, Spain, 2Hospital Clínic de Barcelona, Barcelona, Spain, 3Hospital del Mar, Radiology, Barcelona, Spain, 4Hospital del Mar, Rheumatology, Barcelona, Spain, 5Hospital del Mar, Barcelona, Spain

    Background/Purpose: Joint involvement in SLE is the most frequent manifestation and shows a wide heterogeneity (1) . It has not a valid classification and it…
  • Abstract Number: 1413 • ACR Convergence 2022

    Early Muscle Involvement in Patients with Rheumatoid Arthritis: A Large-Scale Cross-Sectional Study

    Jie Pan1, Yao-Wei Zou1, Ying-Ying Zhu2, Jian-da Ma3, Jian-Zi Lin3, Tao Wu1, Ze-Hong Yang2, Xue-Pei Zhang1, Qian Zhang1, Hu-Wei Zheng1, Xiao-Ling He4, Wan-Mei Cheng4 and Lie Dai3, 1Sun Yat-Sen University, Guangzhou, China, 2Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, 3Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, 4Shanghai Healthare Co. Ltd, Shang hai, China

    Background/Purpose: Muscle loss is common in long-standing rheumatoid arthritis (RA) patients. However, less is known about this unfavorable alteration of body composition (BC) and its…
  • « Previous Page
  • 1
  • …
  • 379
  • 380
  • 381
  • 382
  • 383
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology